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Although integrin avb3 is linked to cancer progres-
sion, its role in epithelial development is unclear.
Here, we show that avb3 plays a critical role in
adult mammary stem cells (MaSCs) during preg-
nancy. Whereas avb3 is a luminal progenitor marker
in the virgin gland, we noted increased avb3 expres-
sion in MaSCs at midpregnancy. Accordingly, mice
lacking avb3 or expressing a signaling-deficient re-
ceptor showed defective mammary gland mor-
phogenesis during pregnancy. This was associated
with decreased MaSC expansion, clonogenicity,
and expression of Slug, amaster regulator ofMaSCs.
Surprisingly, avb3-deficient mice displayed normal
development of the virgin gland with no effect on
luminal progenitors. Transforming growth factor b2
(TGF-b2) induced avb3 expression, enhancing Slug
nuclear accumulation and MaSC clonogenicity. In
human breast cancer cells, avb3 was necessary
and sufficient for Slug activation, tumorsphere for-
mation, and tumor initiation. Thus, pregnancy-asso-
ciated MaSCs require a TGF-b2/avb3/Slug pathway,
which may contribute to breast cancer progression
and stemness.
INTRODUCTION
In the adult mammary gland, an epithelial hierarchy has been
characterized that involves the stepwise differentiation of mam-
mary stem cells (MaSCs)/progenitor cells toward mature luminal
and basal/myoepithelial cell fates (Visvader, 2009). MaSCs/pro-
genitor cells share a number of biological and biochemical prop-
erties with highly invasive breast cancer cells (Visvader, 2009)
and thus may act as the cells of origin for more aggressive types
of breast cancer (Jeselsohn et al., 2010; Lim et al., 2009). Molec-
ular profiling of mammary cells at distinct stages of differentia-
tion identified gene signatures associated with particular MaSCs
and progenitor cells (Lim et al., 2010; Pece et al., 2010). The
MaSC gene expression signature, in particular, correlates with
tumors that are less differentiated (Lim et al., 2010) and representDevelopclinically advanced disease (Pece et al., 2010). In some breast
cancers, a subset of tumor cells has been identified that shares
similar gene expression (Pece et al., 2010) and behavioral prop-
erties (Al-Hajj et al., 2003) with normal MaSCs and are referred to
as cancer stem cells (CSCs).
Integrins act as key cell surface receptors regulating adhe-
sion-dependent functions critical for MaSC/progenitor behavior
(Taddei et al., 2008) and breast carcinogenesis (Desgrosellier
and Cheresh, 2010). Integrin avb3, in particular, is expressed in
some of the most highly malignant tumor cells in carcinomas
of the breast, pancreas, lung, and prostate (Desgrosellier and
Cheresh, 2010), where it may play an anchorage-independent
role in tumor progression (Desgrosellier et al., 2009). Expression
of b3 (CD61) in breast carcinoma cells promotes both lymph
node (Desgrosellier et al., 2009) and bone metastases (Felding-
Habermann et al., 2001; Liapis et al., 1996; Sloan et al., 2006; Ta-
kayama et al., 2005) and serves as a marker of CSCs in some
murine (Vaillant et al., 2008) and human (Seguin et al., 2014) tu-
mors. In the normal murine mammary gland, surface b3 repre-
sents a marker of luminal progenitor cells (Asselin-Labat et al.,
2007) andmay be expressed onMaSCs (Bai and Rohrschneider,
2010), particularly in response to steroid hormones (Joshi et al.,
2010). This suggests that avb3’s function in carcinoma cells may
be related to a role in normal MaSC/progenitor cell behavior.
The epithelial hierarchy in the adult mammary gland repre-
sents a well-characterized system with rigorously defined
markers (Asselin-Labat et al., 2007; Shackleton et al., 2006;
Stingl et al., 2006), allowing us to characterize a possible role
for avb3 in this process. Here, we describe a role for avb3 in
regulating Slug activation in MaSCs leading to MaSC expansion
and mammary gland remodeling during pregnancy. Interest-
ingly, avb3 also promotes Slug activation, anchorage-indepen-
dent growth, and tumor initiation in human breast cancer cells,
hallmarks of tumor stemness.
RESULTS
b3 Is Required for Mammary Gland Development
during Pregnancy
Previous studies showed b3 surface expression in luminal pro-
genitors and some MaSCs from dissociated virgin mammary
glands (Asselin-Labat et al., 2007). Consistent with these find-
ings, we observed b3 expression in basal cells and a subset of
luminal cells within the ducts of adult virgin mice (Figure 1A)mental Cell 30, 295–308, August 11, 2014 ª2014 Elsevier Inc. 295
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Figure 1. b3 Is Specifically Required for
Mammary Gland Development during
Pregnancy
(A) Representative images of b3 immunohisto-
chemistry in an adult virgin murine mammary
gland. Shown is an example of a duct (left panel)
with areas in boxes shown at high power (right
panels). Images on right show b3-expressing cells
(arrows) in the basal epithelial cell layer (top, right)
and a subset of luminal epithelial cells (bottom,
right). Scale bars, 50 mm (left panel) and 10 mm
(right panels).
(B) Western blot of whole-mammary gland lysates
for b3 and a-SMA (loading control). n = 3 mice for
each stage.
(C) Mammary gland whole mounts from virgin and
P12.5 WT and b3KO mice. Virgin, WT (n = 8) and
b3KO (n = 7); P12.5, WT (n = 19) and b3KO (n = 10).
Scale bars, 5 mm (low magnification) and 500 mm
(high magnification).
(D) Representative H&E-stained sections from WT
and b3KO P12.5 mammary glands. Scale bars,
500 mm.
(E) Quantitation of duct/alveoli density in P12.5 WT
versus b3KO H&E-stained mammary gland sec-
tions (WT, n = 13; b3KO, n = 10; p = 0.015). Data
shown represent the mean ± SEM and were
analyzed by Student’s t test. *p < 0.05.
(F) qPCR results displaying the relative amount of
GATA-3 and ELF5 mRNA in WT and b3KO P12.5
mammary glands (WT, n = 11; b3KO, n = 9). Each
sample was run in triplicate, and glyceraldehyde 3-
phosphate dehydrogenase was used as a loading
control. Data are displayed as the mean ± SD. Fold
change (2-DDCT) in b3KO glands is relative to WT.
See also Figures S1 and S2.
Developmental Cell
avb3 Drives Stemness in Pregnancy and Cancerthat was confirmed by costaining with basal and luminal markers
(Figure S1A available online). These results show that the b3
expression pattern in the intact adult mammary gland is consis-
tent with a potential role for b3 in luminal progenitors andMaSCs.
The adult murine mammary gland is a highly dynamic organ,
constantly changing in response to hormones released during
the estrus cycle and pregnancy. Analysis of b3 in whole-mam-
mary gland lysates showed no differences during the estrus cy-
cle (Figure S1B); however, relative to virgin glands, we observed
increased b3 expression during early and midpregnancy that
declined by late pregnancy (Figure 1B). Notably, the peak levels
of b3 at pregnancy day 12.5 (P12.5) coincide with the maximum
number of MaSCs reported during pregnancy (Asselin-Labat
et al., 2010).
b3 expression in glands from both virgin and pregnant mice
suggests a potential function for this receptor in mammary gland
morphogenesis at either stage. To address this possibility, we
examined the morphology of mammary gland whole mounts
from virgin and P12.5 wild-type (WT) and b3 knockout (b3KO)
mice, which lack b3 expression in the mammary gland (Fig-
ure S1C). Although no differences were observed in mammary
glands from virgin b3KO mice (Figure 1C, left panels), marked
differences were seen in b3KOmammary glands at P12.5, which
demonstrated fewer fine branches and alveolar buds relative to
WT glands (Figure 1C, right panels). Importantly, this defect
was maintained throughout late-stage pregnancy and lactation296 Developmental Cell 30, 295–308, August 11, 2014 ª2014 Elsevie(Figures S1D and S1E) and correlated with decreased viability
of litters born to b3KO dams (Figure S1F). However, we noted
no difference in the ability of b3KO alveoli to produce milk at
any stage examined (Figure S2A). Quantification of duct/alveoli
density in hematoxylin and eosin (H&E)-stained sections showed
a nearly 40% decrease in the density of P12.5 b3KO glands
relative to WT controls (Figures 1D and 1E), consistent with the
qualitative assessment of these glands. Thus, b3 appears to be
required for mammary development during pregnancy but not
for ductal morphogenesis in the virgin adult gland.
To discern a potential mechanism that accounts for this
phenotype, we assessed the relative amounts of epithelial cell
proliferation, apoptosis, and differentiation in WT and b3KO
P12.5mammary glands. Quantitative RT-PCR fromwhole-mam-
mary glands showed reduced mRNA levels of the alveolar
marker ELF5 (57% decrease), but not the luminal differentiation
marker GATA3, in P12.5 b3KO mammary glands relative to WT
controls (Figure 1F). In contrast, we were unable to detect any
effect on proliferation (Figures S2B and S2C) or apoptosis, which
was essentially absent from the P12.5 gland (data not shown).
Importantly, we noted similar levels of nuclear ELF5 protein in
b3KO alveoli compared to those from WT mice (Figure S2D),
indicating that the decreased ELF5 mRNA levels observed in
P12.5 b3KO mammary glands are consistent with fewer alveoli
and not due to dysregulated ELF5 expression. Taken together,
these data show that b3 deletion is associated with defectiver Inc.
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Figure 2. b3 Expression Is Increased in
MaSCs during Pregnancy
(A and B) FACS analysis of MaSC/progenitor
markers in virgin and P12.5 WT mammary glands.
(A) Representative FACS density plots showing the
live, LinCD24+ cells expressed according to their
CD29 (b1 integrin) and b3 status.
(B) Histograms showing the percentage of
LinCD24+b3+ cells that are CD29lo or CD29hi. p
values for virgin versus P12.5 are the following:
CD29lo, p = 0.00014; CD29hi, p = 0.00008. Data
shown are mean ± SEM and were analyzed by
Student’s t tests. ***p < 0.001. (A and B) Virgin, n =
8, P12.5, n = 13.
(C) qPCR data showing the relative levels of av and
b3 mRNA in virgin and P12.5 CD29hi cells. Virgin,
n = 2 (pooled from two mice each); P12.5, n = 3.
Each sample was run in triplicate, and 18S rRNA
was used as a loading control. Data are displayed
as the mean ± SEM fold change (2-DDCT) in P12.5
relative to virgin glands.
(D) Immunoblot of FACS LinCD24+ CD29lo and
CD29hi mammary cells from two different P12.5
WT mice for b3, SMA (basal marker), and b-actin
(loading control).
(E) Matrigel colonies from live LinCD24+b3+ and
b3 cells sorted from virgin or P12.5 WT mice.
Virgin, n = 4 (p = 0.00003); P12.5, n = 4 (p = 0.0014).
Data represent the mean ± SEM and were
analyzed by paired Student’s t tests. ***p < 0.001.
(F–H) Mammary gland outgrowth experiments.
(F) Representative images of carmine-stained
mammary gland outgrowth whole mounts from
P12.5 LinCD24+b3+ and b3 donor cells. Re-
cipients were harvested at lactating day 2. Scale
bars, 2 mm.
(G) Bar graph showing the frequency of successful
mammary gland outgrowths from 10,000
LinCD24+b3+ and b3 donor cells from P12.5
mice. Statistical analysis was performed by
Fisher’s exact test. p = 0.006. **p < 0.01.
(H) Representative image of immunohistochemical
staining for E-cadherin (brown) and aSMA (red) in
sections from LinCD24+b3+ cell outgrowths.
Scale bar, 100 mm. (F–H) b3, n = 22, b3+, n = 21
mammary glands from three independent experi-
ments.
See also Figure S3.
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avb3 Drives Stemness in Pregnancy and Cancerinitiation of alveologenesis during pregnancy, suggesting that
b3KO mice may display a defect in MaSCs/progenitor cells.
Pregnancy Is Associated with Increased b3 Expression
in MaSCs
Mammary gland remodeling and differentiation during preg-
nancy require the coordinated response of multiple cell types,
includingMaSCs and progenitors (Asselin-Labat et al., 2010; Je-
selsohn et al., 2010; van Amerongen et al., 2012; Van Keymeulen
et al., 2011). To determine which MaSC/progenitor cell types
might require b3 during pregnancy, we first compared b3
expression in WT virgin and P12.5 mammary glands by flow cy-
tometry. Analysis of live (propidium iodide negative) lineage-
negative (Lin; CD31, CD45, Ter119) mammary cells for
surface expression of CD24 and CD29 (b1 integrin) identifies
enriched populations of mature luminal and progenitor cellsDevelop(CD24+CD29lo) as well as basal and MaSCs (CD24+CD29hi) in
both virgin (Shackleton et al., 2006) and P12.5 mammary glands
(Asselin-Labat et al., 2010). We then evaluated surface b3 levels
in these live LinCD24+CD29hi/lo cells to determine the MaSCs/
progenitor cells that express b3 during pregnancy. We found
that most b3+ cells in the virgin gland resided in the CD29lo pop-
ulation, and the percentage of b3+CD29lo cells decreased during
pregnancy, as previously described by Asselin-Labat et al.
(2007) (Figures 2A and 2B), though some b3+ luminal cells re-
mained (Figures S3A and S3B). However, to our surprise, we
observed increased b3 surface levels on the P12.5 CD29hi
MaSC-enriched population compared to the virgin gland (Fig-
ures 2A, 2B, S3A, and S3B). Interestingly, this effect is concur-
rent with the expansion of the CD29hi MaSC pool at this stage
(Figure 2A) (Asselin-Labat et al., 2010). This increased b3 level
was transient because it decreased to that of virgin glands aftermental Cell 30, 295–308, August 11, 2014 ª2014 Elsevier Inc. 297
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Figure 3. b3 Is Required for MaSC Expansion during Pregnancy
(A and B) FACS analysis of WT and b3KO virgin and P12.5 mammary glands.
(A) Representative FACS density plots of WT and b3KO P12.5 mammary cells showing the live, Lin cells expressed according to their CD24 and CD29 status.
(B) Quantitation of the total number of FACS live LinCD24+CD29hi and CD29lo cells from virgin and P12.5 mammary glands. p values for WT versus b3KO at
P12.5 are as follows: MaSC, p = 0.027; Luminal, p = 0.09. (A and B) Virgin, WT (n = 4) and b3KO (n = 4); P12.5, WT (n = 7) and b3KO (n = 8).
(C) Histogram showing the relative levels of total repopulating cells in the CD29hi pool from WT and b3KO P12.5 donor mice (n = 4 independent experiments).
(B and C) Data represent the mean ± SEM, and statistical analysis was performed by Student’s t tests. *p < 0.05. (B) n.s., not significant (p > 0.05).
(D) Representative images of carmine-stained WT and b3KO outgrowths harvested at lactating day 2. Scale bars, 1 mm.
See also Figure S4.
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levels in P12.5 CD29hi cells corresponded to a nearly 4-fold in-
duction of b3 mRNA compared to virgin CD29hi cells, with little
effect on av levels (Figure 2C), suggesting that this effect is
due to enhanced b3 expression in these cells. Accordingly,
P12.5 b3+CD29hi cells expressed basal markers (Figures 2D
and S3D), consistent with b3 costaining with basal markers in
P12.5 mammary sections (Figure S3B). These data show that
b3 expression is dynamically regulated in CD29hi MaSCs/basal
cells at midpregnancy compared to the virgin gland.
Consistent with b3 expression in CD29hi MaSCs/basal cells
during pregnancy, we observed that b3+ epithelial cells
(LinCD24+b3+) from P12.5 mice were unable to form colonies
in Matrigel compared to b3 cells (Figure 2E). However, these
same cells from virgin mice were enriched for Matrigel colony-
forming cells, in agreement with their characterization as luminal
progenitors (Asselin-Labat et al., 2007) (Figure 2E). Thus, in addi-
tion to differences in CD29 status, b3 expression during preg-
nancy is associated with a functionally distinct cell population
compared to luminal progenitors identified in the virgin mam-
mary gland.
Accordingly, we examined whether b3+ epithelial cells from
P12.5 mice were enriched for MaSCs capable of repopulating
a fully functional mammary gland similar to CD29hi cells (Asse-
lin-Labat et al., 2010; Shackleton et al., 2006). We tested this
possibility by injecting 10,000 LinCD24+b3+ and b3 mammary298 Developmental Cell 30, 295–308, August 11, 2014 ª2014 Elseviecells from the same donor mice into cleared fat pads of wean-
ling recipients and examining repopulating potential. To simul-
taneously assess differences in functionality, all outgrowths
were harvested at lactating day 2. Although few outgrowths
were observed in mice injected with b3 cells (27%), b3+
cells were enriched for repopulating potential (71%) (Figures
2F and 2G), similar to CD29hi cells (Asselin-Labat et al., 2010;
Shackleton et al., 2006). Successful outgrowths all appeared
swollen with milk (Figures 2F and 2H), and the presence of
both luminal and basal cell types was validated by immunohisto-
chemistry (Figure 2H). These data show that during pregnancy,
epithelial expression of b3 is associated with a previously unde-
scribed population of pregnancy-associated MaSCs.
b3 Is Required for Expansion of Pregnancy-Associated
MaSCs
During pregnancy, the proportion of CD29hi MaSCs/basal cells
increases dramatically compared to CD29lo luminal cells (Fig-
ure 2A), resulting in an overall increase in MaSC number
compared to the virgin gland (Asselin-Labat et al., 2010). Based
on the increased b3 surface expression we observed in P12.5
CD29hi cells, we considered whether b3 is required for expan-
sion of MaSCs at this stage. We observed that loss of b3 from
P12.5 CD29hi cells (Figure S4A) decreased the percentage of
CD29hi cells relative to CD29lo cells (Figures 3A and S4B). Sorted
cell counts showed a similar decrease in the number of CD29hir Inc.
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avb3 Drives Stemness in Pregnancy and CancerMaSCs in P12.5 b3KO mice with little or no effect on CD29lo
luminal cells (Figure 3B). Interestingly, loss of b3 did not affect
the number of either cell type in virgin glands, consistent with
the absence of a role for b3 in luminal progenitors or MaSCs at
this stage (Figure 3B). These findings support a specific role for
b3 in regulating expansion of the MaSC-enriched subset during
pregnancy.
This defect in CD29hi cell expansion suggests that b3
deletion may result in fewer repopulating cells at midpregnancy.
To address this, we performed limiting dilution mammary
gland-transplantation assays with CD29hi cells from WT and
b3KO P12.5 mammary glands. Results from these experiments
showed decreased repopulating frequency in b3KO CD29hi cells
(Figure S4C) that corresponded to a 3.6-fold decrease in the
absolute number ofMaSCs relative toWTmice (Figure 3C). In or-
der to simultaneously test the functionality of these transplants,
all outgrowths were harvested on lactating day 2. Interestingly,
we noted similar levels of ductal elongation and lobular develop-
ment in b3KO outgrowths compared to WT (Figure 3D), consis-
tent with the lack of a role for b3 in ductal morphogenesis in
the adult gland (Figure 1C) or alveolar maturation during late
pregnancy and lactation (Figures S1D, S1E, and S2A). Accord-
ingly, b3 deletion failed to affect the number of lobule-limited
progenitors present within the CD29hi cell pool (Figure S4D).
The more limited outgrowths generated by lobule progenitors
are defined by the absence of terminal end bud-like ductal ex-
tensions preventing invasion of the fat pad (Bruno and Smith,
2011; Jeselsohn et al., 2010; Smith and Medina, 2008) (Fig-
ure S4E). Taken together, these observations highlight a critical
role for b3 expression in specifically regulating MaSC expansion
during midpregnancy.
b3 Signaling Is Required for MaSC Clonogenicity
during Pregnancy
Decreased MaSC expansion in pregnant b3KO mice suggests a
possible defect in MaSC clonogenicity. To evaluate this role for
b3, we examined mammary cells from virgin or P12.5 WT or
b3KO mice for colony formation on irradiated mouse embryonic
fibroblasts (MEFs). In order to preserve the luminal-basal cross-
talk present in the intact mammary gland, we used total mam-
mary cells for these experiments. In this assay, MaSCs and
progenitor cells form colonies that can be distinguished based
onmorphology (Stingl, 2009) (Figure 4A, top panels) and expres-
sion of luminal (E-cadherin) or basal (smoothmuscle actin [SMA])
markers (Jeselsohn et al., 2010) (Figure 4A, bottom panels).
Luminal progenitors form densely packed colonies that express
only E-cadherin, basal progenitors form loose colonies that ex-
press only SMA, and MaSCs form mixed colonies that express
both E-cadherin and SMA (Jeselsohn et al., 2010; Stingl, 2009).
Examining colony morphology by this method, we observed
that the proportion of MaSC-like mixed colonies increases at
P12.5 (Figure 4A, left panels, and Figure 4C) compared to virgin
glands (Figure 4B), consistent with the increased frequency of
MaSCs observed at P12.5 (Asselin-Labat et al., 2010). Unex-
pectedly, examination of colonies from WT and b3KO mice
showed that b3 deletion had no effect on MaSCs or luminal col-
onies in virgin mice, despite b3 acting as a marker of luminal pro-
genitor cells at this stage (Asselin-Labat et al., 2007) (Figure 4B).
However, loss of b3 significantly decreased the frequency ofDevelopMaSCs and basal colonies at P12.5 compared to WT mice (Fig-
ure 4C), with a reciprocal increase in luminal colonies (Figure 4A,
right panels, and Figure 4C). Importantly, b3 deletion did not
appear to affect total colony number (Figure 4D). The decreased
percentage of MaSC colonies in b3KO mice could alternatively
be explained by an increase in luminal progenitors. To directly
address this possibility, we performedMatrigel colony-formation
assays with WT and b3KO CD29lo-sorted cells from virgin or
P12.5 mice and observed no effect of b3 deletion on luminal pro-
genitor cells at either stage (Figure 4E). These data highlight a
specific role for b3 in regulatingMaSC clonogenicity during preg-
nancy, whereas having no effect on luminal progenitors in either
the virgin or pregnant mammary gland.
In addition to their role as cell-adhesion receptors, integrins
activate important signaling pathways influencing a diverse array
of cell behaviors, including proliferation, survival, and migration.
To examine a role for b3 signaling in MaSC/progenitor behavior,
we analyzed knockin mice expressing a signaling-deficient b3
mutant lacking only the last three amino acids of the b3 cyto-
plasmic domain (b3DC) (Ablooglu et al., 2009). This mutant pre-
vents the interaction with c-Src and other signaling proteins
(Arias-Salgado et al., 2003), resulting in deficient b3 signaling,
but does not influence ligand binding (Ablooglu et al., 2009;
Arias-Salgado et al., 2003; Desgrosellier et al., 2009). Impor-
tantly, previous studies showed that cells from b3DC knockin
mice express similar levels of b3 protein compared to those
from WT mice, and the b3DC mutant forms functional integrin
avb3 heterodimers capable of mediating adhesion to b3 sub-
strates (Ablooglu et al., 2009), which we validated in P12.5 mam-
mary glands (Figures S5A–S5D). Similar to the b3KO (Figures 4B
and 4C), no differences were found in colonies from virgin b3DC
mice (Figure 4F), yet we observed fewer MaSC colonies from
b3DC mice at P12.5, with proportionally more luminal colonies
(Figure 4G). As observed in b3KO mice, total colony number
was unchanged upon b3DC expression (Figure S5E), and Matri-
gel assays showed no difference in luminal progenitor cell num-
ber (Figure S5F). In fact, examination of P12.5 b3DC mammary
glandwholemounts (Figure S5G) andH&E-stained sections (Fig-
ure 4H) showed fewer fine branches and alveoli relative to WT
mice, similar to the phenotype observed in b3KO mice. These
results reveal a role not only for b3 expression but, more specif-
ically, the b3 cytoplasmic signaling domain in contributing to
P12.5 MaSC clonogenic activation and mammary gland devel-
opment during pregnancy.
TGF-b2 Stimulates b3 Expression, Enhancing
MaSC Clonogenicity
Although hormones like progesterone have been shown to in-
crease b3 expression in MaSCs/basal cells of ovariectomized
mice (Joshi et al., 2010), this is unlikely to be a direct effect
because MaSCs lack steroid hormone receptors (Asselin-Labat
et al., 2006). Therefore, to investigate the factors that may
account for b3 expression in MaSCs during pregnancy, we eval-
uated several paracrine factors associated with pregnancy, such
as transforming growth factor b (TGF-b) family members and
receptor activator of nuclear factor kB ligand (RANKL). Impor-
tantly, both RANKL and TGF-b ligands are increased during
pregnancy (Asselin-Labat et al., 2010; Fata et al., 2000;
Monks, 2007; Robinson et al., 1991), and both pathways affectmental Cell 30, 295–308, August 11, 2014 ª2014 Elsevier Inc. 299
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Figure 4. b3 Signaling Is Required for Pregnancy-Associated MaSC Colony Formation
(A) Representative images ofWT and b3KOP12.5 colonymorphology on irradiated fibroblasts by crystal violet staining (top panels) or immunofluorescent staining
for E-cadherin and SMA (bottom panels). Nuclei are stained blue in all panels. Arrows mark SMA-positive cells. Scale bars, 100 mm.
(B–D) Quantitation of the percent MaSC, basal, and luminal colonies (B and C) and total colony number (D) from virgin and P12.5 WT and b3KO mice. Virgin, WT
(n = 6) and b3KO (n = 6); P12.5, WT (n = 5) and b3KO (n = 4). (C) p values for WT versus b3KO at P12.5 are as follows: MaSC, p = 0.0004; Basal, p = 0.005; Luminal,
p = 0.0004. (D) n.s., not significant (p > 0.05).
(E) Histogram depicting colony formation in Matrigel from FACS CD29lo WT and b3KO cells from virgin and P12.5 mice. Virgin, WT (n = 4) and b3KO (n = 4); P12.5,
WT (n = 4) and b3KO (n = 4).
(F and G) MaSC, basal, and luminal colonies formed from virgin (F) or P12.5 (G) WT and b3DC mammary cells grown on irradiated MEFs. Virgin, WT (n = 2) and
b3DC (n = 2); P12.5, WT (n = 5) and b3DC (n = 4).
(H) Quantitation of duct/alveoli density in P12.5 WT versus b3DC H&E-stained mammary gland sections. WT, n = 12, b3DC, n = 20.
(B–H) Data represent the mean ± SEM, and statistical analysis was performed by Student’s t tests. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S5.
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avb3 Drives Stemness in Pregnancy and Cancerdevelopment of the pregnant mammary gland (Fata et al., 2000;
Gorska et al., 2003). Furthermore, RANKL and TGF-b ligands are
known to regulate b3 expression in other systems (Galliher and
Schiemann, 2006; Lacey et al., 1998).
To examine the ability of these factors to increase b3 expres-
sion, we stimulated cells from virgin WT mice and measured b3
expression in MaSCs/basal cells, defined by expression of K14
and SMA. Unexpectedly, we found that TGF-b2, but not TGF-
b1 or RANKL, stimulated b3 expression in MaSCs/basal cells
relative to vehicle-treated cells (Figure 5A). Quantitative PCR
(qPCR) analysis confirmed TGF-b2’s ability to drive b3 mRNA
expression specifically in CD29hi MaSCs/basal cells because lit-
tle effect was observed in CD29lo luminal cells from the same300 Developmental Cell 30, 295–308, August 11, 2014 ª2014 Elseviemice (Figures 5B and 5C). Similar effects were observed in hu-
man mammary epithelial cells (HMECs), including MCF10As
where TGF-b2 was a potent driver of b3 expression (Figure 5D).
Indeed, we found that TGF-b2 was capable of directly activating
the b3 promoter in these cells as determined using a luciferase
reporter plasmid containing the proximal 1,300 bp of the b3 pro-
moter upstream of the initial start site (Figure 5E). Although
TGF-b family members commonly induce activation of the
SMAD family of transcription factors, analysis of the b3 promoter
failed to identify any SMAD consensus binding elements as
assessed by querying the ENCODE whole-genome data in the
UCSC genome browser (Raney et al., 2011). However, SMADs
commonly exert their transcriptional effects through interactingr Inc.
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avb3 Drives Stemness in Pregnancy and Cancerwith SP1 (Feng et al., 2000; Jungert et al., 2006; Poncelet and
Schnaper, 2001), which has previously been shown to directly
bind the b3 promoter (Evellin et al., 2013). Accordingly, knock-
down of SP1 potently blocked TGF-b2-induced b3 mRNA and
protein expression (Figures 5F and 5G).
The ability of TGF-b2 to drive b3 expression suggested that
this ligand may affect MaSC clonogenicity in a b3-dependent
manner. Compared to vehicle, only TGF-b2 increased the fre-
quency of bipotent, MaSC-like colonies grown on irradiated
MEFs (Figure 5H), with a reciprocal decrease in luminal colonies
(Figure 5H), an effect similar to that observed in cells from preg-
nant mice (Figures 4B and 4C). This effect was reduced in mam-
mary cells from b3KOmice (Figure 5H), similar to our results from
pregnant b3KOmice (Figure 4C). TGF-b2 did not affect total col-
ony number unlike TGF-b1, which had a severe growth inhibitory
effect, and RANKL, which acted as a potent driver of colony
formation (Figure 5I). Notably, b3 did not contribute to colony
number in response to any of these factors, consistent with re-
sults from P12.5 b3KO mice (Figure 4D). Taken together, these
data show that TGF-b2, a critical growth factor released during
pregnancy, stimulates b3 expression in MaSCs/basal cells and
enhances MaSC clonogenicity in a b3-dependent manner.
b3 Mediates Slug Activation in Response to TGF-b2
and Pregnancy
The bipotent MaSC-like colonies observed in response to
TGF-b2 possess morphological characteristics reminiscent of
an epithelial-mesenchymal transformation (EMT) (Figure 5H).
This is consistent with a relationship between EMT genes and
MaSC/progenitor cell behavior (Guo et al., 2012), particularly
during pregnancy (Chakrabarti et al., 2012). Additionally, TGF-b
family members are well characterized for their ability to stimu-
late EMT in development (Moustakas and Heldin, 2007) and
cancer (Katsuno et al., 2013). Consistent with this, TGF-b2 stim-
ulation of MCF10A cells drives changes in the expression of EMT
markers such as Slug, E-cadherin, and Vimentin (Figure S6A).
Although TGF-b2 induced similar effects on EMT marker protein
expression in WT, but not b3KO 2D colonies from virgin mice
(Figures S6B and S6C), no such changes in mRNA expression
were noted in sorted CD29hi or CD29lo cells (Figure S6D).
Thus, TGF-b2-stimulated changes in colony morphology (Fig-
ure 5H) are consistent with increased formation of MaSC-like
bipotent colonies, and not an EMT transition of either luminal
or basal cell types.
Despite the apparent absence of an effect on EMT, Slug
protein levels were consistently reduced in TGF-b2-stimulated
b3KO 2D colonies compared to WT, specifically in the
K14+SMA+ MaSCs/basal cells (Figure S6C). Slug was recently
characterized as a determinant of the MaSC fate in the virgin
mammary gland (Guo et al., 2012) and is expressed during early
to midpregnancy but is negatively regulated by Elf5 during late-
stage pregnancy/lactation, allowing for alveolar maturation
(Chakrabarti et al., 2012). Therefore, we considered whether b3
was required for TGF-b2-mediated Slug expression in MaSCs/
basal cells. In virginWTmammary cells, TGF-b2 induced nuclear
Slug expression specifically in K14+SMA+ cells compared to
cells treated with a vehicle control (Figures 6A and 6B). In
contrast, TGF-b2 failed to increase Slug in b3KO cells (Figures
6A and 6B), highlighting an essential role for b3 in TGF-b2-stim-Developulated Slug protein expression in MaSC-enriched basal cells,
despite the absence of an effect on Slug mRNA (Figure S6D).
Given that TGF-b2 expression is induced during pregnancy
(Robinson et al., 1991), we hypothesized that b3 may similarly
regulate Slug expression in the pregnant mammary gland.
Compared to WT glands, we observed dramatically reduced
levels of nuclear Slug in the K14+ basal cells of P12.5 b3KO
mice (Figures 6C and 6D). Despite this decrease in Slug protein
levels, Slug mRNA was unaffected in b3KO P12.5 CD29hi cells
(Figure S6E), similar to the effects observed in TGF-b2-stimu-
lated cells (Figures S6D and S6F). Thus, b3 appears to play an
integral role in regulating Slug protein expression in MaSC-en-
riched basal cells in response to TGF-b2 or pregnancy with no
effect observed on Slug mRNA.
To determine the potential mechanism by which avb3 regu-
lates Slug, we considered whether avb3 signaling may be
required by assessing whether the b3DC mutant affects Slug
expression. Whereas TGF-b2 induced Slug in K14+SMA+ mam-
mary cells from virgin WT mice, no increase was observed in
cells from b3DC knockin mice (Figure 6E). The b3DC mutant
has previously been characterized as defective in recruiting
and activating Src family kinases (SFKs) (Ablooglu et al., 2009;
Arias-Salgado et al., 2003; Desgrosellier et al., 2009). Consistent
with this, we noted decreased levels of SFK activation (pY416
SFK) in TGF-b2-stimulated K14+SMA+ MaSCs/basal cells from
b3DC virgin mice compared toWT cells (Figure S7A), suggesting
that avb3-mediated SFK activation may be required for Slug
expression. Indeed, transient b3 knockdown in MCF10A cells
significantly reduced TGF-b2-induced pY416 SFK and Slug
expression (Figure 6F), with no effect observed on Slug mRNA
(Figure S6F). Interestingly, treatment with an avb3 function-
blocking antibody (LM609) failed to affect SFK activation or
Slug expression (Figure S7B), suggesting that this role for avb3
may be ligand independent. The absence of an effect on Slug
mRNA suggested that avb3 may regulate Slug protein through
an alternative mechanism. Indeed, Slug protein levels are highly
regulated through degradation by the proteasome (Kim et al.,
2012; Wu et al., 2012). We found that short-term incubation
with a proteasome inhibitor (MG132) was sufficient to restore
Slug protein levels to normal in b3 knockdown cells with little
effect on Slug levels in control cells (Figure 6F). Accordingly,
short-term incubation with the SFK inhibitor dasatinib reduced
only the TGF-b2-induced Slug protein expression (Figure 6G).
Thus, it appears that TGF-b2-stimulated expression of avb3 me-
diates SFK activation resulting in enhanced Slug protein stability.
avb3 Is Associatedwith Slug Activation and Stemness in
Human Breast Cancer Cells
Previous studies showed that Slug promotes properties associ-
ated with both MaSCs and aggressive stem-like breast cancer
cells (Guo et al., 2012; Proia et al., 2011). Our observation that
avb3 regulates Slug in pregnancy-associated MaSCs prompted
us to investigate whether a similar relationship exists in human
breast cancer cells. Indeed, using gain- and loss-of-function ap-
proaches (Figures 7A–7C and S7C–S7F), we found that ectopic
expression of b3 was sufficient to drive Slug nuclear accumula-
tion in both MCF-7 and MDA-MB-468 human breast cancer
cells, which lack endogenous b3 (Figures 7A, 7C, S7D, and
S7F), whereas b3 small hairpin RNA (shRNA) knockdown in amental Cell 30, 295–308, August 11, 2014 ª2014 Elsevier Inc. 301
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Figure 5. TGF-b2 Stimulates b3 Expression, Enhancing MaSC Clonogenicity
(A) Representative immunofluorescent images of b3 expression in K14+SMA+ cells (arrows) from pooled virgin WT mammary cells stimulated with the indicated
growth factors. Nuclei are stained blue in all panels. Scale bars, 20 mm. Data shown are representative of three independent experiments.
(B and C) qPCR analysis comparing the relative levels of b3 mRNA in vehicle versus TGF-b2-stimulated CD29hi (B) and CD29lo (C) cells fromWT virgin mice. n = 2
independent experiments (pooled samples).
(D) Immunoblot for b3 and b-actin (loading control) in MCF10As and HMECs stimulated with TGF-b2 or vehicle control. Data shown are representative of three
independent experiments.
(E) Histogram displaying the relative luciferase activity in MCF10A cells transfected with an empty vector (Ctrl) or a luciferase reporter plasmid containing the
proximal region of the b3 promoter (b3 prom-Luc) and stimulated with vehicle or TGF-b2. n = 3 independent experiments. p = 0.043.
(F and G) A representative experiment showing the effect of SP1 knockdown on b3 mRNA (F) and protein (G) expression in MCF10A cells stimulated with TGF-b2
or vehicle control. MCF10A cells transfected with control (siCtrl) or SP1 small interfering RNA (siRNA) (siSP1) were analyzed for b3mRNA expression by qPCR (F)
or b3 protein by immunoblot (G) in the same experiment. n = 3 independent experiments.
(B, C, and F) Each sample was run in triplicate, and 18S rRNA (B and C) or b-actin (F) was used as loading controls. Data are displayed as the mean ± SEM fold
change (2-DDCT).
(legend continued on next page)
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avb3 Drives Stemness in Pregnancy and Cancerhighly metastatic (HM) variant of the MDA-MB-231 cells (Munoz
et al., 2006) reduced nuclear Slug levels compared to control
cells expressing a nonsilencing shRNA (Figures 7B and S7E).
Notably, even unligated avb3 was capable of driving Slug
expression, as assessed with a b3 mutant deficient in ligand
binding (b3 D119A) (Desgrosellier et al., 2009) (Figure S7C).
This is consistent with the inability of avb3 antagonists to inhibit
Slug expression in nontransformed cells (Figure S7B) and sug-
gests a ligand-independent role for avb3. Additionally, the
b3DC mutant was defective in Slug expression compared to
full-length b3 (Figures 7C and S7F), in agreement with our obser-
vations from mice (Figure 6E). Thus, b3 is both necessary and
sufficient for Slug activity in human breast cancer cells in addi-
tion to regulating Slug expression in pregnancy-associated
MaSCs in the mouse.
These findings suggest that avb3 may promote stem-like
properties in tumor cells, which we assessed by tumorsphere
formation in vitro and limiting dilution tumor-initiation experi-
ments in vivo. Consistent with the role of unligated avb3 in
promoting Slug expression, stable b3 knockdown in triple-
negative BT-20 and MDA-MB-231 (HM) cells resulted in fewer
anchorage-independent tumorspheres relative to controls (Fig-
ures 7D, S7E, and S7G). Additionally, b3 knockdown in MDA-
MB-231 (HM) cells reduced the number of tumor-initiating cells
compared to control when injected orthotopically into adult fe-
male mice at limiting dilution (Figures 7E and 7F). Importantly,
b3 knockdown had no effect on primary tumor mass in these
experiments (Figure 7G), indicating that avb3 has a specific
effect on tumor-initiating cells and does not affect basic prolif-
erative and survival responses necessary for primary tumor
growth, similar to the effects observed in the mammary gland
due to b3 deletion. Together, our findings highlight a conserved
role for avb3 leading to Slug activity associated with MaSC
expansion during pregnancy and stem-like properties in breast
cancers.
DISCUSSION
Integrin avb3 is found in some of themost aggressive tumor cells
in a diverse array of carcinomas including breast cancer, where it
is associated with enhanced tumorigenicity and metastasis
(Desgrosellier et al., 2009; Felding-Habermann et al., 2001; Lia-
pis et al., 1996; Sloan et al., 2006; Takayama et al., 2005), yet
it is unclear if this is related to a role in epithelial stem/progenitor
cells. We now show that avb3 plays a specific role in driving
MaSC expansion during pregnancy. Genetic deletion of the in-
tegrin b3 subunit, or expression of a signaling-deficient form of
this receptor, resulted in defective mammary gland development
during pregnancy with no effect on ductal morphogenesis in the
virgin gland. This phenotype was associated with increased
expression of b3 in the MaSC-enriched pool at midpregnancy,
an effect reproduced by stimulation with TGF-b2 (Figure 7H). Ex-
amination of MaSC and progenitor cell activity showed that b3
was specifically required for MaSC clonogenicity, expansion,(H and I) Quantitation of the percent MaSC/basal and luminal colonies (H) and tota
with the indicated growth factors. n = 3 independent experiments. (H) p values fo
p = 0.0071. p values for WT versus b3KO cells stimulated with TGF-b2 are as fo
(E, H, and I) Data represent the mean ± SEM, and statistical analysis was perform
Developand Slug expression during pregnancy with no effect on luminal
progenitor cells.
Distinct MaSC/progenitor populations contribute to the devel-
opment, maintenance, and remodeling of the adult mammary
gland (Asselin-Labat et al., 2010; Spike et al., 2012; Van Keymeu-
len et al., 2011; Wagner et al., 2002). Adult MaSC behavior is
highly sensitive to steroid hormones released during the estrus
cycle and pregnancy (Asselin-Labat et al., 2007, 2010; Joshi
et al., 2010), and these pregnancy-induced MaSCs possess
distinct properties compared to MaSCs in the virgin gland, such
as more limited self-renewal (Asselin-Labat et al., 2010). Addi-
tionally, some MaSCs/progenitors are retained postpregnancy
in the parous gland where they represent a functionally distinct
population of parity-induced cells (Matulka et al., 2007). We
observed thatb3 levels associatedwithMaSCsduringpregnancy
were transient, diminishing to levels found in virgin mice after
involution. Thus, b3-expressing MaSCs are unlikely to represent
parity-induced cells. Instead, our findings characterize integrin
avb3 as a critical determinant of the MaSC state duringmidpreg-
nancy, and a requirement for avb3 serves to distinguish these
cells from MaSCs required for maintenance in the virgin gland.
To our surprise, b3 was not required for luminal progenitor cell
function despite characterization of b3 as a surface marker of
luminal progenitor cells in the virgin mammary gland (Asselin-
Labat et al., 2007). Although our findings show that b3 enriches
for luminal progenitors in the virgin gland, consistent with others
(Asselin-Labat et al., 2007), genetic deletion of b3 had no effect
on luminal progenitor cell clonogenicity or ductal morphogen-
esis. This is consistent with other reports where genetic deletion
of b3 had no effect on ductal morphogenesis in virgin adult
murine mammary glands (Taverna et al., 2005). Thus, a potential
role for avb3 in tumor cell clonogenicity may be linked to its
expression on MaSCs during pregnancy rather than on luminal
progenitors.
The steroid hormone progesterone is critical for mammary
gland remodeling during pregnancy and regulates b3 expression
in MaSCs (Joshi et al., 2010). However, MaSCs lack the proges-
terone receptor (Asselin-Labat et al., 2006), suggesting that pro-
gesterone regulates MaSCs indirectly through stimulating
release of paracrine factors such as TGF-b and RANKL during
pregnancy (Asselin-Labat et al., 2010; Fata et al., 2000; Monks,
2007; Robinson et al., 1991). We show that the TGF-b family
member TGF-b2, and not TGF-b1 or RANKL, drives b3 expres-
sion in MaSCs/basal cells enhancing MaSC clonogenicity.
Similar to our observations regarding b3 expression and function
during pregnancy, progesterone and TGF-b family members are
critically expressed early in pregnancy and are reduced in late
pregnancy, allowing lobular maturation (Gorska et al., 2003;
Jhappan et al., 1993; Monks, 2007; Robinson et al., 1991).
Thus, integrin avb3 may function as a key molecular switch
downstream of progesterone-TGF-b signaling that promotes
the activation of the MaSC pool during early pregnancy and is
reduced in late pregnancy allowing for alveolar secretory
maturation.l colony number (I) from pooled virgin WT and b3KOmammary cells stimulated
r vehicle versus TGF-b2 in WT cells are as follows: MaSC, p = 0.0071; Luminal,
llows: MaSC, p = 0.0413; Luminal, p = 0.0413.
ed by Student’s t tests. *p < 0.05; **p < 0.01.
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Figure 6. b3 Is Required for Slug Activation in Response to TGF-b2 or Pregnancy
(A and B) Slug expression in K14+SMA+ cells from virgin WT and b3KO mammary cells stimulated with vehicle or TGF-b2.
(A) Representative images of Slug expression in K14+SMA+ cells (arrows). Scale bars, 20 mm.
(B) Quantitation of the percentage of Slug+K14+SMA+ cells. p = 0.0439 (vehicle versus TGF-b2 in WT cells) and p = 0.0342 (WT versus b3KO cells stimulated with
TGF-b2). (A and B) WT, n = 3, b3KO, n = 3.
(C and D) Slug expression in WT and b3KO P12.5 mammary glands.
(C) Representative images of Slug in K14+ cells (arrows). Scale bars, 20 mm. (A and C) Nuclei are stained blue in all panels.
(D) Histogram showing the relative levels of nuclear Slug expression. Data for each mouse represent the average nuclear Slug expression from five fields
normalized to total nuclear stain. p = 0.0113. (C and D) WT, n = 8, b3KO, n = 6.
(E) Quantitation of the percentage of Slug-expressing K14+SMA+ cells from virgin WT and b3DC mammary cells stimulated with vehicle or TGF-b2. WT, n = 2,
b3DC, n = 2. p = 0.029 (vehicle versus TGF-b2 in WT cells) and p = 0.032 (WT versus b3DC cells stimulated with TGF-b2).
(B, D, and E) Data represent the mean ± SEM, and statistical analysis was performed by Student’s t tests. *p < 0.05.
(legend continued on next page)
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avb3 Drives Stemness in Pregnancy and CancerPregnancy-associated breast cancers represent some of the
most aggressive breast cancers due to frequent metastasis
(Schedin, 2006). Interestingly, recent studies have shown that
pregnancy is a major regulator of MaSC number and function,
suggesting a relationship betweenMaSCs and pregnancy-asso-
ciated breast cancers (Asselin-Labat et al., 2010). Accordingly,
some proteins that regulate MaSCs during pregnancy also
have important functions in aggressive breast tumors (Gonza-
lez-Suarez et al., 2010; Schramek et al., 2010). Our findings
reveal a specific role for integrin avb3 in regulating Slug expres-
sion and MaSC expansion during pregnancy. In breast cancer
cells, avb3 also appears to be necessary and sufficient for
Slug activity, anchorage-independent growth, and tumor initia-
tion, properties of stem-like cancer cells (Figure 7H). These find-
ings highlight a potential relationship between avb3’s function in
pregnancy-associated MaSCs and aggressive stem-like breast
cancers.
EXPERIMENTAL PROCEDURES
Histological Analysis, Immunohistochemistry, and
Immunofluorescence
For immunohistochemical staining of formalin-fixed paraffin-embedded tis-
sues, antigen retrieval was performed in citrate buffer at pH 6.0 and 95C
for 20 min. Sections were blocked in normal goat serum diluted in PBS, incu-
bated overnight at 4C in primary antibody, followed by biotin-conjugated
anti-rabbit immunoglobulin G and an avidin-biotin peroxidase detection sys-
tem with 3,30-diaminobenzidine substrate (Vector Laboratories), then coun-
terstained with hematoxylin. Whole-mount mouse mammary glands were
fixed in Carnoy’s solution and stained with carmine. For quantitation of
duct/alveoli density, three to four images were randomly sampled from
H&E-stained paraffin sections from each mouse with a 43 objective and
analyzed with MetaMorph software. For immunofluorescence, frozen sec-
tions or fixed cells were blocked with normal goat serum in PBS and incu-
bated in primary antibody overnight at 4C followed by secondary at room
temperature for 1 hr. For further details, see Supplemental Experimental
Procedures.
Lysates and Immunoblotting
Whole-mammary gland lysates were prepared by pulverizing glands flash
frozen in liquid nitrogen with a mortar and pestle and then lysing the tissue
with radio-immunoprecipitation assay lysis buffer (RIPA) lysis buffer. The
lysate was further processed with a handheld tissue homogenizer and cleared.
Whole-cell lysates were prepared from cell lines with RIPA lysis buffer com-
bined with scraping. Standard western blotting procedures were performed.
See Supplemental Experimental Procedures for further details.
Flow Cytometry and Mammary Outgrowth Assays
Single-cell suspensions were prepared and stained with antibodies as
described in detail in Supplemental Experimental Procedures. Cell sorting
was performed using a FACSDiva or FACSAria (BD Biosciences). For
outgrowth experiments, sorted cells were injected into the cleared abdominal
fat pads of 3-week-old syngeneic recipients. Estimated repopulating cell fre-
quencies were calculated using the ELDA web-based tool (Hu and Smyth,
2009) (http://bioinf.wehi.edu.au/software/elda/). All experiments involving
mice were conducted under protocols approved by the UCSD animal subjects
committee and are in accordance with the guidelines set forth in the NIH Guide
for the Care and Use of Laboratory Animals.(F and G) Immunoblots of MCF10A cells stimulated with TGF-b2 or vehicle contr
(F) Cells were transfected with control (Ctrl) or b3 siRNA and additionally treated
(G) Cells were treated with 100 nM Src inhibitor (dasatinib) for the indicated le
independent experiments.
See also Figures S6 and S7.
DevelopMammary Colony Assays
For colony formation on irradiated MEFs, 100,000 MEFs were seeded into
6-well dishes for 48 hr prior to adding 40,000 cells from digested mammary
glands and grown in complete Dulbecco’s modified Eagle’s medium
(DMEM). Colonies formed over 5–6 days before fixing and staining with either
0.1% crystal violet/20% methanol/PBS or 2% paraformaldehyde/PBS for
immunofluorescent staining and counting colonies. For Matrigel colonies,
5,000 fluorescence-activated cell sorting (FACS) mammary gland cells were
suspended in 50 ml growth factor-reduced Matrigel (BD PharMingen) and
grown 14 days in serum-free mammary epithelial cell medium-basal medium
(Cambrex) supplemented with B27 supplement, 20 ng/ml epidermal growth
factor, 20 ng/ml basal fibroblast growth factor, 4 mg/ml heparin, 100 U/ml peni-
cillin, and 100 mg/ml streptomycin. Total colonies per well were counted from
each of the four replicates per experiment.
Growth Factor and Inhibitor Experiments
Cells from digested mammary glands were seeded at 40,000 cells per well
onto MEFs (for colony-formation assays) or 8-well chamber slides (Lab-Tek)
coated with 2%Matrigel/DMEM. At the time of seeding, cells were suspended
in complete DMEM supplemented with vehicle (0.1% BSA/PBS), RANKL
(50 ng/ml), TGF-b1 (5 ng/ml), or TGF-b2 (5 ng/ml) (PeproTech). Cells were fixed
with 2% paraformaldehyde/PBS after 48 hr (chamber slides) or 5 days (col-
onies) for immunofluorescent staining.
For experiments with MCF10A and HMECs, TGF-b2 stimulations were per-
formed with 5 ng/ml TGF-b2 (PeproTech) or 0.1% BSA/PBS (vehicle) for 48 hr
prior to lysis. In some experiments, 30 mg/ml of the anti-avb3 function-blocking
antibody LM609 (Millipore) was added to cells at the same time as TGF-b2 or
vehicle addition. For the proteasome inhibitor experiments, 10 mM MG132
(Sigma-Aldrich) or DMSO (vehicle) was added to transfected MCF10A cells
5 hr prior to lysis. Treatment of MCF10A cells with the SFK inhibitor dasatinib
(ChemieTek) or DMSO (vehicle) was performed with 100 nM dasatinib for the
indicated times prior to harvesting lysates.
Orthotopic Breast Cancer
Tumors were generated by injection of MDA-MB-231 (HM) cells expressing
nonsilencing or b3 shRNA at limiting dilution (in 50 ml sterile PBS) into the
inguinal fat pads of adult (12 weeks) female nonobese diabetic/severe com-
bined immunodeficiency/interleukin-2 receptor g chain knockout mice. Mice
were monitored weekly for tumor formation by gentle palpation. Primary tumor
mass was determined by assessing the wet weight of the resected tumors. All
tumors formed within 5 weeks, and all tumor-bearing mice were harvested at
6weeks. Tumor-freemicewere harvested at 13weeks, and the absence of any
detectable tumor was confirmed by whole-mount staining.
Statistical Analyses
Data presentation and statistical tests are indicated in the figure legends. For
all analyses, p < 0.05 was considered statistically significant.SUPPLEMENTAL INFORMATION
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Figure 7. avb3 Is Associated with Slug Activation and Stemness in Human Breast Cancer Cells
(A–C) Representative immunofluorescent images showing Slug expression in (A) MCF-7 cells stably transfected with b3 cDNA or vector alone (Control), (B) a HM
variant ofMDA-MB-231 cells stably expressing a nonsilencing (shCtrl) or b3 shRNA (shb3), and (C)MDA-MB-468 cells stably expressing vector control, full-length
b3 or the b3DC mutant. (A–C) Nuclei are stained blue in all panels. Scale bars, 20 mm.
(D) Histogram depicting the results of b3 knockdown on soft agar colony number in MDA-MB-231 (HM) or BT-20 human tumor cell lines compared to control.
MDA-MB-231 (HM), n = 3, p = 0.0079, BT-20, n = 2, p = 0.031.
(E–G) In vivo tumor initiation studies comparing control and b3 knockdown MDA-MB-231 (HM) cells injected orthotopically into adult female mice at limiting
dilution.
(E) Table describing the frequency of tumor formation per fat pad injected for each cell type.
(F) Histogram showing the estimated number of tumor-initiating cells from the data in (E).
(G) Bar graph depicting the primary tumor mass for each cell type in tumors formed after injection of 10,000 cells and harvested at 6 weeks.
(legend continued on next page)
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